1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. UniQure N.V.
  6. Notizie
  7. Altre lingue
    QURE   NL0010696654

UNIQURE N.V.

(QURE)
  Rapporto
Tempo differito Nasdaq  -  23/05 22:00:01
13.36 USD   -2.62%
06/05UNIQURE N.V.: Stifel Nicolaus ancora positivo
MM
03/05UNIQURE N.V.: da Credit Suisse è Buy
MM
03/05UNIQURE N.V.: Goldman Sachs mantiene la raccomandazione Buy
MM
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su UNIQURE N.V.
11/05uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/05UniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/05uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell ..
02/05UniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell ..
02/05UNIQURE N: 2021 Dutch Statutory IFRS Financials
02/05Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $1.8M
02/05UniQure Reports Wider Q1 Loss, Higher Revenue
02/05UNIQURE N.V. Management's Discussion and Analysis of Financial Condition and Results o..
02/05UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2022
02/05UNIQURE: Q1 Earnings Snapshot
02/05uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Pr..
02/05UniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Pr..
29/03CSL Behring - European Medicines Agency Commences Review of Novel Gene Therapy Candidat..
28/03European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene..
22/03UNIQURE N: Announces Completion of Patient Enrollment in the First Two Cohorts of its Pha..
22/03UNIQURE N.V.: Other Events, Financial Statements and Exhibits (form 8-K)
21/03UniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phas..
21/03UniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phas..
17/03UniQure Shares Gain After Upgrade by UBS
03/03Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
28/02UNIQURE N: Announces 2021 Financial Results and Highlights Recent Company Progress - Form..
25/02SECTOR UPDATE: Health Care Stocks Mixed Pre-Bell Friday
25/02UniQure Swings to 2021 Profit, Revenue Increases; Shares Rise Pre-Bell
25/02UNIQURE N.V. Management's Discussion and Analysis of Financial Condition and Results o..
25/02UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2021
25/02UniQure Announces 2021 Financial Results and Highlights Recent Company Progress
08/02UNIQURE N: Announces Dosing of First Patients in European Open-Label Clinical Trial of AM..
08/02UNIQURE N.V.: Other Events, Financial Statements and Exhibits (form 8-K)
07/02Uniqure Doses First Two Patients in Huntington's Disease Trial
07/02UniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT..
07/02UniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT..
04/02UNIQURE N.V.: Entry into a Material Definitive Agreement (form 8-K)
04/02EAHAD 2022 - FINAL ANALYSIS FROM THE: Stable Steady-State Efficacy and Safety of Etranaco..
04/02Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic E..
20/01Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ..
2021UniQure Unit Enters Into $6.5 Million Lease Agreement in Massachusetts
2021UNIQURE N.V.: Entry into a Material Definitive Agreement (form 8-K)
2021UNIQURE N: Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AM..
2021UNIQURE N.V.: Entry into a Material Definitive Agreement, Creation of a Direct Financial ..
2021uniQure N.V. Enters into Third Amended and Restated Loan and Security Agreement
2021Health Care Up On Defensive Bias -- Health Care Roundup
2021Global biotherapeutics - CSL Behring Receives Accelerated CHMP Assessment for Etranacog..
2021UniQure Says Initial Data From Phase 1/2 Trial Support Tolerability of AMT-130 in Patie..
2021TRANSCRIPT: uniQure N.V. - Special Call
2021uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT..
2021uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT..
2021CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for Euro..
2021UNIQURE N: and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of ..
2021UNIQURE N.V.: Other Events, Financial Statements and Exhibits (form 8-K)
2021CSL Behring and uniQure N.V. Announce Etranacogene Dezaparvovec, an Investigational Ade..
2021Health Care Stocks Lower Ahead of Thursday Open
2021UniQure, CSL Behring Say Late-Stage Trial of Hemophilia Treatment Meets Primary Endpoin..
2021uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of E..
2021uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of E..
2021INSIDER SELL: Uniqure
2021UniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in P..
2021UniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board in Pha..
2021UniQure to Participate in Upcoming Industry Conferences in November
2021UNIQURE N: Announces Third Quarter 2021 Financial Results and Highlights Recent Company P..
2021UNIQURE N: Management's Discussion and Analysis of Financial Condition and Results of Ope..
2021UNIQURE N: Narrows Loss in Q3, Revenue Climbs
2021UniQure N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
2021UNIQURE: Q3 Earnings Snapshot
2021UNIQURE N: Earnings Flash (QURE) UNIQURE Reports Q3 Revenue $2M
2021UNIQURE N: Announces Third Quarter 2021 Financial Results and Highlights Recent Company P..
2021UNIQURE N.V.: Submission of Matters to a Vote of Security Holders (form 8-K)
2021UNIQURE N: ESGCT 2021 - Pre-Clinical Proof of Concept of an AAV5-GLA Gene Therapy for Fab..
2021UNIQURE N: Announces the Appointment of Rachelle Jacques to its Board of Directors
2021UniQure N.V. Appoints Rachelle Jacques?to its Board of Directors
2021TRANSCRIPT: uniQure N.V. - Shareholder/Analyst Call
2021UNIQURE N: Announces Presentations at the Annual Meeting of The European Society of Gene ..
2021INSIDER SELL: Uniqure
2021UNIQURE N: to Participate in Multiple Upcoming Industry Conferences in October
2021INSIDER SELL: uniQure
2021UNIQURE N.V.(NASDAQGS: QURE) added to S&P 600
1  2  3  4  5  6  7  8Pross.
Prossimo evento su UNIQURE N.V.